Search Result

Your Search for:ivermectin 3mg online kaufen deutschland 🤙🏽🥛 Apothekenlink: 🇩🇪 AllForHeal.net 🇩🇪 🥛 🤙🏽 ivermectin 3mg kaufen rezeptfrei 🧈 🧈


Chi-Med Highlights Surufatinib Phase III Results in Neuroendocrine Tumors at ESMO 2020 and Publications in The Lancet Oncology

…access to treatment options. [4] Xu J, Shen L, Zhou Z, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study [published online ahead…


Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

…placebo-controlled, phase 3 study [published online ahead of print, 2020 Sep 20]. Lancet Oncol. 2020; S1470-2045(20)30496-4. DOI: 10.1016/S1470-2045(20)30496-4. [5] Xu J, Shen L, Bai C, et al. Surufatinib in advanced…


Chi-Med Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs

…line with guidance Group revenue up 12% to $241.2 million (2016: $216.1m); Net loss attributable to Chi-Med $26.7 million (2016: Net profit $11.7m), including $88.0 million in research and development…


Chi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference of the European Neuroendocrine Tumor Society

…and immune evasion. Five other sulfatinib clinical trials are underway in China and the U.S., including two Phase III studies in NET patients (SANET-p and SANET-ep), one Phase II study…


Chi-Med Reports 2020 Interim Results and Provides Updates on Key Clinical Programs

…in May 2020 and subsequent grant of Priority Review status in July 2020. Surufatinib – Two NDAs with first China launch in NET planned for late 2020: Progressed non-pancreatic NET


Chi-Med Reports 2017 Interim Results and Updates Shareholders on Key Clinical Programs

…$126.6 million (H1 2016: $104.5m). Net income attributable to Chi-Med of $1.7 million (H1 2016: $0.5m), including $37.5 million in research and development expenses on an as adjusted basis (H1…


Chi-Med Announces Second NDA Acceptance in China for Surufatinib in Pancreatic Neuroendocrine Tumors

…Society for Medical Oncology Congress (“ESMO”) (Abstract Number 1156O). This is the second NDA acceptance for surufatinib. The first NDA for non-pancreatic NET was accepted by the NMPA in November…


Chi-Med Reports Final Results for the Year Ended December 31, 2016 and Updates on Key Clinical Programs

…Hutchison China MediTech Limited (“Chi-Med”) Reports Final Results for the Year Ended December 31 , 2016 and Updates Shareholders on Key Clinical Programs Group: Record revenue, net income and…


Chi-Med Reports 2018 Full Year Results and Provides Updates on Key Clinical Programs

…(2017: $241.2m). N et loss attributable to Chi‑Med of $74.8 million (2017: net loss $26.7m). Adjusted Group net cash flow (non-GAAP) was -$57.3 million in 2018. Cash from our Commercial…


Chi-Med Reports 2019 Full Year Results and Provides Updates on Key Clinical Programs

…another two NDA3 submissions are imminent, one with savolitinib in lung cancer and a second with surufatinib in pancreatic NET, with launches anticipated for 2021.” “Based on extensive clinical data,…


Chi-Med Reports 2019 Interim Results and Provides Updates on Key Clinical Programs

…Chairman, Chi-Med. “All major clinical readouts in the first half were encouraging, with the stand-out results being surufatinib’s positive Phase III outcome in non-pancreatic NET and savolitinib’s preliminary data in…


Final Results for the year ended 31 December 2015

…104% to $178.2 million (2014: $87.3m). Net profit from operations attributable to Chi-Med of $8.0 million (2014: net loss -$7.3m), including our booking of $3.1 million in one-time preparation costs…


Chi-Med Plans to Submit Marketing Authorization Application for Surufatinib Following Scientific Advice from EMA’s CHMP

…that the completed SANET-ep (non-pancreatic NET) and SANET-p (pancreatic NET) studies, along with existing data from surufatinib in U.S. non-pancreatic and pancreatic NET patients, could form the basis to support…


Chi-Med Plans to Submit NDA for Surufatinib Following Pre-NDA Meeting with the U.S. FDA

…SANET-p (pancreatic NET) studies, along with existing data from surufatinib in U.S. non-pancreatic and pancreatic NET patients, could form the basis to support a U.S. NDA submission. The FDA granted…


Chi-Med Reports Interim Results for the Six Months Ended June 30, 2016, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs

…to $ 8 2 .3 million ( H1 201 5: $55.6m); Total sales of non-consolidated joint ventures up 9% to $249.6 million (H1 2015: $229.8m); Total net income attributable to…


Chi-Med initiates sulfatinib U.S. clinical trials

…tumours. A U.S. Phase II study in NET is expected to be initiated based on the conclusion of this Phase I dose escalation study. Sulfatinib is an oral drug candidate…


Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine Tumors

…(SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study [published online ahead of print, 2020 Sep 20]. Lancet Oncol. 2020; S1470-2045(20)30496-4. DOI: 10.1016/S1470-2045(20)30496-4. [3] According to Frost & Sullivan. In 2018,…


Chi-Med Reports 2018 Interim Results and Updates Shareholders on Key Clinical Programs

…Chi‑Med of $32.7 million (H1 2017: net profit $1.7m). Cash resources of $416.9 million at Group level as of June 30, 2018 ($479.6m as of December 31, 2017), including cash…


Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Safety Data Presented at the 2019 ESMO Annual Meeting

…– – Preparations underway for the potential submission of surufatinib New Drug Application (“NDA”) by year end 2019 for non-pancreatic NET tumors in China – – Treatment options are limited…


Chi-Med Initiates a Phase II Trial of Surufatinib in Combination with Tuoyi in Patients with Advanced Solid Tumors

NET was accepted for review by the NMPA, and the U.S. Food and Drug Administration granted Orphan Drug designation to surufatinib for the treatment of pancreatic NET.   About Surufatinib…


Initiation of sulfatinib Phase III registration study in neuroendocrine tumour patients

…placebo-controlled, multi-centre Phase III sulfatinib registration study to treat pathologically low or intermediate grade NET patients whose disease has progressed, locally advanced or distant metastasised and for whom there is…


Final Results for the year ended 31 December 2014

…Results (IFRS11) Revenue up 100% to $91.8 million (2013: $46.0m). Net profit attributable to Chi-Med equity holders of $ 5.4 million (2013: $5.9m) as the Company continues to balance a…


Chi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors

…the development of surufatinib, for the treatment of both advanced and progressive pancreatic neuroendocrine tumors (“NET”) and extra-pancreatic (non-pancreatic) NET in patients who are not amenable for surgery. The FDA…


Interim Results for the Six Months Ended 30 June 2015

…progressing well – evidence of the strength and adaptability of our Commercial Platform to enter new therapeutic areas in future, including oncology and immunology. New factories: Coming online at the…


Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing

…Raise and Offering do proceed, Chi‑Med intends to use the net proceeds of the potential Equity Raise, together with the cash generated by its operations, primarily to advance the clinical…


Financial Highlights

…and joint ventures (excluding non-consolidated joint ventures) of Chi-Med. OVERALL GROUP: Group revenue of $204.9 million (2018: $214.1m). Net loss attributable to Chi-Med of $106.0 million (2018: net loss of…


Chi-Med’s New Drug Application for Surufatinib in Non-Pancreatic Neuroendocrine Tumors Granted Priority Review in China

…treatment of non-pancreatic NET. Surufatinib being granted priority review is a positive step forward in potentially bringing this innovative drug to patients, who currently have very limited treatment options.” In…


Chi-Med Highlights Presentations of Surufatinib at the Upcoming AACR Virtual Annual Meetings

…Phase III studies of surufatinib in NET in China, and the ongoing multi-cohort Phase Ib study in the U.S. (clinicaltrials.gov identifier: NCT02549937). In the U.S., surufatinib was granted Fast Track…


ESMO2020: Surufatinib for patients with advanced pancreatic NET (SANET-p)

…Department of Gastrointestinal Oncology, The Fifth Medical Center, General Hospital of the PLA Session: Proffered Paper – NETs Abstract Number: 1156O Date & Time: Sunday, September 20, 2020 2:25 PM…


Repeat of Announcement of Fifth Public Filing of Registration Statement on Form F-1 and Launch of Potential U.S. Public Offering of ADSs

…price. Chi-Med has applied to have its ADSs approved for listing on the Nasdaq Stock Market under the symbol “HCM.” In addition to the net proceeds which may be generated…


Fifth Public Filing of Registration Statement on Form F-1 and Launch of Potential U.S. Public Offering of ADSs

…Market under the symbol “HCM.” In addition to the net proceeds which may be generated by the Offering, Chi-Med plans to continue to utilize its various resources, including existing cash…


Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Sulfatinib in Pancreatic Neuroendocrine Tumors and Biliary Tract Cancer in the United States

…This study follows several trials that are underway in China, including two Phase III studies in pancreatic and non-pancreatic NET that commenced after positive results from a Phase II study,…


Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company

…as detailed below:   2018 Previous Guidance 2018 Current Guidance Adjustment Group Level: · Consolidated revenue $155-175m $155-175m None · Admin., interest & tax $(16)-(18)m $(16)-(18)m None · Net loss[1]…


Chi-Med Initiates a Phase IIb/III Trial of Surufatinib in Patients with Unresectable or Metastatic Biliary Tract Cancer in China

…in proof-of-concept clinical trials in the U.S. and several proof-of-concept and late-stage clinical trials in China. Pancreatic NET in China: In 2016, we initiated the SANET-p study, which is a…


Chi-Med initiates sulfatinib Phase III registration study in pancreatic neuroendocrine tumor patients

…grade advanced NET whose disease has progressed, locally advanced or distant metastasized and for whom there is no effective therapy. Patients are randomized at a 2:1 ratio to receive either…


ENETS 2017: Sulfatinib Phase Ib/II in Advanced Neuroendocrine Tumors

…sulfatinib monotherapy in patients with advanced grade 1 or 2 advanced NET. 81 patients (41 pancreatic NET and 40 extra-pancreatic NET) were enrolled between November 2014 and January 2016, in…


Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancreatic Neuroendocrine Tumors

NET was accepted for review by the China National Medical Products Administration (NMPA) on November 11, 2019.   About FDA Orphan Drug Designation The FDA Orphan Drug Designation Program provides…


Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab

…of surufatinib in NET in China, and the ongoing multi-cohort Phase Ib study in the U.S. (clinicaltrials.gov identifier: NCT02549937). In the U.S., surufatinib was granted Fast Track Designations for development…


Chi-Med Announces NDA Acceptance in China for Surufatinib in Non-Pancreatic Neuroendocrine Tumors

…the potential approval and launch of surufatinib in China, an important development for NET patients with limited treatment options. In order to maximize patient access to surufatinib upon regulatory approval,…


Chi-Med initiates sulfatinib Phase II clinical trial in thyroid cancer

…and Cancer Therapeutics in early November 2015 (www.chi-med.com/sulfatinib-ph1-eortc-2015/). The Phase I clinical data indicates that sulfatinib has a superior ORR in NET patients. An ORR of 44% was observed for…


Sulfatinib clinical results and fruquintinib-savolitinib combination preclinical results to be presented at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference

…objective response rate among the 18 efficacy-evaluable NET patients was 44.4% and disease control rate was 100%. By comparison, sunitinib and everolimus, the two approved single agent therapies for neuroendocrine…


Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-ep Phase III Trial at ESMO Annual Meeting

…September 29. Safety and tolerability data presented from an ongoing U.S. Phase Ib study of surufatinib in pancreatic NET patients who have progressed on Sutent® or Afinitor® treatment will also…


Chi-Med Highlights Clinical Data to be Presented at the Upcoming ESMO Virtual Congress 2020

…of patients with advanced non-pancreatic NET was accepted for review by the China National Medical Products Administration (“NMPA”) and granted Priority Review status in December 2019. A second NDA for…


Chi-Med to Discuss Select Global Clinical Trial Data Presented at ASCO20

…survival hazard ratio of 0.51 with median not reached ― ― Ongoing surufatinib study in U.S. progressive NET patients demonstrated promising efficacy irrespective of prior lines of therapy ― ―…


Chi-Med Highlights Clinical Data to be Presented at the Upcoming ASCO20 Virtual Scientific Program

…be very suitable for possible combinations with other immunotherapies. A New Drug Application (“NDA”) for surufatinib for the treatment of patients with advanced non-pancreatic NET was accepted for review by…


Chairman’s Statement

…this year in non-pancreatic NET. Our first NDA for surufatinib was granted Priority Review following our submission in late 2019, and preparation for a second NDA in pancreatic NET is…


EORTC 2015: First-in-human phase I study of selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors

…tumours (NETs). Eight NET patients (5 in 300mg QD and 3 in 350mg QD cohort) had confirmed partial response (PR) with median duration of response (DoR) of 13.8 months. The…


News & Presentations

…as it becomes available online. — Aruba Afghanistan Angola Anguilla Åland Islands Albania Andorra United Arab Emirates Argentina Armenia American Samoa Antarctica French Southern Territories Antigua and Barbuda Australia Austria…


Privacy Policy

…Hutchison China MediTech Limited 2019. All rights reserved. Your privacy is important to us. This notice explains our online information practices and the choices you can make about…


Chi-Med Announces that Surufatinib Phase III SANET-p Study Has Already Achieved its Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China and Will Stop Early

…statements reflect Chi-Med’s current expectations regarding future events, including its expectations regarding the NDA approval and launch of surufatinib for the treatment of patients with pancreatic or non-pancreatic NET in…


AACR2020: A Phase I Trial of Surufatinib plus Toripalimab in Patients with Advanced Solid Tumor

…25/30 patients across 3 cohorts were evaluable for tumor response: 1 complete response, 6 partial response (ORR=28%); in NET G1/2 (3), NEC (2), ESCC (1), and CRC (1). Twelve patients…


Financial Results

…surufatinib and savolitinib.” Simon To, Chairman, Mar 3, 2020 Read More FY2019 Financial Summary Group US$ Revenue $204.9m Net income/(loss) ($106.0m) — Innovation Platform Revenue $16.0m Net income/(loss) ($133.2m) —…


Phase I clinical data for selective VEGFR, c-Met and VEGFR/FGFR inhibitors to be presented at the 2014 ASCO Annual Meeting

…cohort, 1 liver neuroendocrine tumour (NET) and 1 NET with unknown primary site in 300mg cohort, and 1 lymph node NET in 350mg cohort. ORR is 30% among the 13…


Analyst Coverage

…BofA MERRILL LYNCH Dr. Alec W. Stranahan+1 646 743 2109 alec.stranahan@bofa.com Dr. Geoff Meacham+1 646 855 1004 geoff.meacham@bofa.com BLOOMBERG Cinney Zhangczhang429@bloomberg.net Sam Fazelimfazeli@bloomberg.net CANACCORD GENUITY Dr. John Newman+1…


Chi-Med Initiates a Phase II Study of Sulfatinib in Second-line Biliary Tract Cancer in China

…SANET-p trial is a randomized, double-blind, placebo-controlled, multi-center, Phase III pivotal registration trial to treat about 190 pathologically low or intermediate grade pancreatic NET patients in China whose disease has…


Chi-Med Presented Pre-clinical Data for Fruquintinib and Sulfatinib at the American Association for Cancer Research Annual Meeting 2017

…underway in China and the United States, including two Phase III studies and one Phase II study in NET patients (SANET-p, SANET-ep and SANET-1), one Phase II study in thyroid…


Chi-Med Announces Proposed Public Offering of ADSs

…for the Offering has not yet been determined. Chi-Med will receive all of the net proceeds from the sale of ADSs in the Offering, if completed, which it intends to…


Chi-Med Files Application to List in Hong Kong and Announces Proposed Global Offering

…Although the final structure and size of the potential Offering is yet to be determined, Chi-Med expects that the net proceeds from any primary sale of Shares in the Offering,…


Chi-Med Announces Pricing of US$110 Million Public Offering of ADSs

…discounts and commissions. The Offering is expected to close on January 27, 2020, subject to customary closing conditions. Chi-Med will receive all of the net proceeds from the sale of…


Bloomberg

…Cinney Zhang czhang429@bloomberg.net Sam Fazeli mfazeli@bloomberg.net


Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market (RNS)

…October 30, 2017. The net proceeds from the Offering are expected to be used to fund the on-going research and development of the Chi-Med Innovation Platform drug pipeline and for…


The Lancet Oncology: Surufatinib SANET-ep phase 3 study

…Funding: Hutchison MediPharma. Trial Registration: ClinicalTrials.gov Identifier: NCT02588170.   Citations and Links Please follow the link below to access the publication: Lancet Oncol. 2020;S1470-2045(20)30496-4. [published online ahead of print, 2020…


The Lancet Oncology: Surufatinib SANET-p phase 3 study

…patient population. Funding: Hutchison MediPharma. Trial Registration: ClinicalTrials.gov Identifier: NCT02589821.   Citations and Links Please follow the link below to access the publication: Lancet Oncol. 2020; S1470-2045(20)30493-9. [published online ahead…


Consumer Health

…infant formula is sold in China through an online retailer and specialty retail outlets. Hutchison Healthcare Our wholly owned subsidiary and is primarily engaged in the manufacture, marketing and distribution…


Warning to Shareholders

…to see if the firm is authorized by FCA. Report the call to the FCA by calling the FCA Consumer Helpline on 0800 111 6768 or complete the online boiler…


Clin Cancer Res: Surufatinib in advanced, well-differentiated neuroendocrine tumors

…  Citations Journal: Clinical Cancer Research June 15, 2019 (25) (12) 3486-3494 (Published Online First March 4, 2019) DOI: 10.1158/1078-0432.CCR-18-2994 PubMed: 30833272   Abstract Purpose: No anti-angiogenic treatment is yet…


CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confirms its intention to hold Chi-Med as a strategic investment for the long term

…or (iii) are persons falling within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations etc.) of the Order; or (iv) are persons to whom an invitation or inducement…


CK Hutchison offers 1.3% of Chi-Med’s share capital aiming to deconsolidate and hold Chi-Med as a strategic investment for the long term

…(iii) are persons falling within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations etc.) of the Order; or (iv) are persons to whom an invitation or inducement to…


TR-1: Form for notification of major holdings

…managers to institutional and high net worth clients. CB&T is a U.S.-based investment management company that is a registered investment adviser and an affiliated federally chartered bank. Neither CGC nor…


Chi-Med Announces Pricing of Upsized U.S. Public Secondary Offering of American Depositary Shares

…“Order”) or (iii) are persons falling within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations etc.) of the Order; or (iv) are persons to whom an invitation or…


Chi-Med Announces Secondary Offering of American Depositary Shares

…(high net worth companies, unincorporated associations etc.) of the Order; or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section…


Disclosure Update

…Article 49(2)(a) to (d) (high net worth companies, unincorporated associations etc.) of the Order; or (iv) any other person to whom it may lawfully be communicated (all such persons in…


Notice of Extraordinary General Meeting and Shareholders’ Circular

…Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) persons falling within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations etc.) of the Order; or (iv)…


Disclosure Update

…of the Financial Services and Markets Act 2000 (Financial e49(2)(a) to (d) (high net worth companies, unincorporated associations etc.) of the Order; or (iv) any other person to whom it…


Chi-Med Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately US$301.3 Million on the Nasdaq Global Select Market

…Services and Markets Act 2000 (Financial Promotion) Order 2005, or the Order, (ii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article…


Chi-Med Announces the Full Exercise of Underwriters’ Over-allotment Option

…Act 2000 (Financial Promotion) Order 2005, or the Order, (ii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d)…


Chi-Med Announces Proposed Offering of ADSs (RNS)

…19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, or the Order, (ii) high net worth entities, and other persons to whom it may lawfully be…


Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market

…The net proceeds from the Offering are expected to be used to fund the on-going research and development of the Chi-Med Innovation Platform drug pipeline and for working capital and…


Chi-Med Commercial Platform Joint Venture Receives US$59.5 Million Land Compensation Payment

net book value of the old site and its buildings, as well as taxes and other costs. The re-zoning of the Site prompted SHPL to build a new factory with…


Closing of U.S. Public Offering of ADSs Raising Approximately US$101 Million on the Nasdaq Stock Market

net worth companies, unincorporated associations etc) of the Order; or (iv) any other person to whom it may lawfully be communicated (all such persons in (i) to (iv) together being…


Final Prospectus

…who fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations etc) of the Order; or (iv) any other person to whom it may lawfully be communicated (all…


Pricing of U.S. Public Offering of ADSs

…(d) (high net worth companies, unincorporated associations etc) of the Order; or (iv) any other person to whom it may lawfully be communicated (all such persons in (i) to (iv)…


Fourth Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing

…Article 49(2)(a) to (d) (high net worth companies, unincorporated associations etc) of the Order; or (iv) any other person to whom it may lawfully be communicated (all such persons in…


Third Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing

…(high net worth companies, unincorporated associations etc) of the Order; or (iv) any other person to whom it may lawfully be communicated (all such persons in (i) to (iv) together…


Second Public Filing of Registration Statement on Form F‑1 for potential Nasdaq Stock Market Listing

…(d) (high net worth companies, unincorporated associations etc) of the Order; or (iv) any other person to whom it may lawfully be communicated (all such persons in (i) to (iv)…


AstraZeneca and Chi-Med enter into global collaboration to co-develop and commercialise novel cancer therapy

…achievement of clinical development and first sale milestones. The agreement also contains possible significant future commercial sale milestones and up to double-digit percentage royalties on net sales. This collaboration further…


Cancer Therapy Collaboration with Lilly

net sales. Additional terms of the agreement were not disclosed. Christian Hogg, Chief Executive Officer of Chi-Med said: “Our belief is that Fruquintinib has potential activity against multiple tumour types…


Our Pipeline

…CSF-1R = colony stimulating factor-1 receptor; Syk = spleen tyrosine kinase; PI3Kδ = Phosphatidylinositol-3-Kinase delta; NSCLC = non-small cell lung cancer; RCC = renal cell carcinoma; NET = neuroendocrine tumors;…


Chi-Med Announces the Exercise of Underwriters’ Over-allotment Option for Public Offering of ADSs

…“Order”) or (iii) are persons falling within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations etc.) of the Order; or (iv) are persons to whom an invitation or…